One Wealth Capital Management LLC Buys Shares of 7,602 Abbott Laboratories (NYSE:ABT)

One Wealth Capital Management LLC purchased a new position in Abbott Laboratories (NYSE:ABT) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 7,602 shares of the healthcare product maker’s stock, valued at approximately $860,000.

Several other hedge funds also recently made changes to their positions in ABT. Lantz Financial LLC grew its position in Abbott Laboratories by 5.2% during the second quarter. Lantz Financial LLC now owns 5,737 shares of the healthcare product maker’s stock worth $596,000 after buying an additional 281 shares in the last quarter. Strategic Financial Concepts LLC bought a new position in shares of Abbott Laboratories in the second quarter worth approximately $116,000. Acadian Asset Management LLC raised its stake in Abbott Laboratories by 510.6% in the second quarter. Acadian Asset Management LLC now owns 319,169 shares of the healthcare product maker’s stock valued at $33,156,000 after purchasing an additional 266,899 shares in the last quarter. Arbor Capital Management Inc. ADV purchased a new position in Abbott Laboratories in the 2nd quarter worth approximately $2,743,000. Finally, Quest Partners LLC increased its holdings in shares of Abbott Laboratories by 482.2% in the 2nd quarter. Quest Partners LLC now owns 18,094 shares of the healthcare product maker’s stock worth $1,880,000 after buying an additional 14,986 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Up 0.3 %

Shares of Abbott Laboratories stock traded up $0.30 during trading on Tuesday, hitting $113.34. The company’s stock had a trading volume of 3,475,594 shares, compared to its average volume of 4,298,638. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $121.64. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The company has a fifty day simple moving average of $115.44 and a two-hundred day simple moving average of $112.31. The company has a market capitalization of $196.58 billion, a PE ratio of 34.45, a P/E/G ratio of 2.69 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.01. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. The company had revenue of $10.64 billion during the quarter, compared to analyst estimates of $10.55 billion. During the same quarter last year, the company earned $1.14 EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Equities research analysts predict that Abbott Laboratories will post 4.67 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be issued a $0.59 dividend. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. The ex-dividend date is Wednesday, January 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 2.08%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 71.73%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Royal Bank of Canada lifted their price objective on shares of Abbott Laboratories from $125.00 to $130.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Sanford C. Bernstein increased their price objective on Abbott Laboratories from $133.00 to $138.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Raymond James restated a “buy” rating and issued a $129.00 target price (up previously from $122.00) on shares of Abbott Laboratories in a research report on Monday, October 14th. Jefferies Financial Group lifted their price target on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a “hold” rating in a research note on Thursday, October 17th. Finally, Barclays increased their target price on shares of Abbott Laboratories from $143.00 to $149.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $131.57.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.